Progression of Parkinson's Disease may be Predicted by Genetic Factors

A new study has found that the speed of clinical deterioration in patients with Parkinson's disease my be influenced by different varieties of a-synuclein gene and its interaction with the microtubule-associated protein tau (MAPT) H1 haplotype.

According to Yue Huang and her team from the University of New South Wales, Sydney, Australia, Parkinson's disease is marked by the abnormal accumulation of a-synuclein NACP-Rep1 and the early loss of dopamine neurons in the substantia nigra region of the brain.

Parkinson’s Disease - Causes, Symptoms, Diagnosis, Treatment
Parkinson’s disease is a neurodegenerative disease caused by progressive dopamine brain cells loss. Symptoms of Parkinson’s disease are correctable to an extent.

A polymorphism in the promotor of NACP-Rep1 has been implicated as a risk factor for the disease.

"Our data are the first to show that polymorphisms of NACP and MAPT interact to influence the rate of progression of Parkinson's disease, a finding with clinical utility," Huang said.

"Our study shows that genotypes for NACP and MAPT can be used as a surrogate marker for the estimated rate of Parkinson's disease progression, with positive predictive values of 94-100 percent for certain genotypes," she said.

Parkinson's Disease
Slide animation on Parkinson disease. It is a progressive movement disorder due to degeneration of nerve cells of the substantia nigra of the brain. The symptoms get worse with time but drugs or surgery can control them. PD cannot be cured.

123 patients with Parkinson's disease underwent genetic testing to determine NACP-Rep 1 and MAPT H1 allele or genotype. The patient's disease severity was measured using the Unified Parkinson's Disease Rating Scale (UPDRS), and a measurement of disease progression was calculated based on detailed information about disease and symptom onset.

Three common variations, or alleles, of NACP-Rep1 were detected. Patients with one '0' NACP-Rep1 allele had significantly slower disease progression compared to two or no '0' carriers.

Parkinson's Disease - Surgical Treatment
Slide animation on surgery for Parkinson disease. Surgery is only indicated where drugs fail to control the symptoms of this progressive movement disorder. Surgery cannot cure the disease.

This may partially reflect the known protective influence of '0' allele on Parkinson's disease. There was a high variation in the estimated rate of disease progression for the '0' allele group due to an interactive effect with the MAPT genotype.

The results of the study showed that a low relative risk for rapid clinical progression in patients with one NACP-1 '0' allele, or those carrying MAPT non-H1H1 genotype with two NACP-Rep1 '0's. In contrast there was a high risk of a fast clinical progression in patients carrying MAPT H1H1 genotype with two or no NACP-Rep1 '0's.

"Based on current knowledge, it is perhaps not surprising that genetic variation predisposing to high a-synuclein expression gives rise to more rapid progression of PD," Huang said.

"However, our results suggest that low a-synuclein expression may also be as detrimental in people with high tau expression levels, calling into question the concept that reducing neuronal a-synuclein in all PD patients may be therapeutically advantageous," she added.

Source-ANI